View source for 20240024302. SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY simplified abstract (BETH ISRAEL DEACONESS MEDICAL CENTER, INC.)

=SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY=


==Organization Name==

[[:Category:BETH ISRAEL DEACONESS MEDICAL CENTER, INC.|BETH ISRAEL DEACONESS MEDICAL CENTER, INC.]]


[[Category:BETH ISRAEL DEACONESS MEDICAL CENTER, INC.]]

==Inventor(s)==

[[:Category:Jeffrey E. Saffitz of Waban MA (US)|Jeffrey E. Saffitz of Waban MA (US)]][[Category:Jeffrey E. Saffitz of Waban MA (US)]]

[[:Category:Bruce D. Hammock of Davis CA (US)|Bruce D. Hammock of Davis CA (US)]][[Category:Bruce D. Hammock of Davis CA (US)]]

[[:Category:Sung Hee Hwang of Woodland CA (US)|Sung Hee Hwang of Woodland CA (US)]][[Category:Sung Hee Hwang of Woodland CA (US)]]

==SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240024302 titled 'SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY

==Simplified Explanation==

The patent application describes methods for preventing, mitigating, decreasing, reversing, and/or treating arrhythmogenic cardiomyopathy (ACM) in a subject. This is achieved by administering an effective amount of a compound of formula I, a compound of formula II, or a compound of formula III to the subject.

* The compound of formula I, compound of formula II, or compound of formula III is administered to a subject in need of treatment for ACM.
* The compounds are effective in preventing, mitigating, decreasing, reversing, and/or treating ACM.
* The compounds are administered in an amount that is effective for the desired treatment outcome.
* The specific values of R, R, R, N, R, R, R, M, R, R, and P are defined in the patent application.

Potential Applications:
* Treatment of arrhythmogenic cardiomyopathy (ACM)
* Prevention of ACM in individuals at risk
* Mitigation of ACM symptoms
* Reversal of ACM progression

Problems Solved:
* Lack of effective treatment options for arrhythmogenic cardiomyopathy
* Limited methods for preventing or mitigating ACM
* Inadequate means for reversing ACM progression

Benefits:
* Improved treatment outcomes for individuals with ACM
* Potential to prevent or delay the onset of ACM
* Reduction in ACM-related symptoms and complications
* Possibility of reversing the progression of ACM


==Original Abstract Submitted==

provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating arrhythmogenic cardiomyopathy (acm) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula i, a compounds of formula ii, or a compound of formula iii (i) (ii), (iii) wherein r, r, r, n, r, r, r, m, r, r, and p are as defined herein.



[[Category:A61K31/4515]]
[[Category:A61K31/415]]
[[Category:A61K31/5377]]
[[Category:A61P9/06]]